Summary
This prediction ended on 16.10.17 with a price of €18.28. The prediction had a final performance of 13.79%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Ablynx NV | - | - | - | - |
| iShares Core DAX® | 1.085% | -1.655% | 13.297% | 57.692% |
| iShares Nasdaq 100 | -1.665% | -3.137% | 2.218% | 83.804% |
| iShares Nikkei 225® | 3.863% | 6.947% | 22.818% | 56.282% |
| iShares S&P 500 | 0.111% | -1.320% | 1.445% | 57.791% |
Comments by melinda for this prediction
In the thread Ablynx NV diskutieren
FOLGEN
Ablynx ( ABLYF.PK ) Montag angekündigt , positive Ergebnisse auf die Grundlinie der Studie der Phase III mit HERCULES caplacizumab, Purpura zur Behandlung von thromboembolischen thrombactique thromboembolischen oder thrombotischen ATTP entwickelt.